Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS-Blessed Warfarin Genetic Testing Trial Aimed At Winning Over Payers and Docs

This article was originally published in The Pink Sheet Daily

Executive Summary

Genetic testing to guide dosing of warfarin is still relevant, even with new competing oral anticoagulants on the rise, says the CEO of Iverson, the diagnostics company sponsoring the trial.

You may also be interested in...



CMS Sets The Stage For New Medicare "Coverage With Evidence Development" Guidance

A rarely-used tool for gathering data on medical technologies will get a fresh look as the agency solicits public comment on how to make CED a more meaningful and effective part of its coverage decision-making process.

With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing

Pharmacy benefits management company Medco Health Solutions Inc. says that with the newly approved oral anticoagulant Pradaxa (dabigatran) off to a good commercial start, it plans to monitor outcomes and compare results with generic warfarin that has been optimized according to genetic testing.

With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing

Pharmacy benefits management company Medco Health Solutions Inc. says that with the newly approved oral anticoagulant Pradaxa (dabigatran) off to a good commercial start, it plans to monitor outcomes and compare results with generic warfarin that has been optimized according to genetic testing.

Related Content

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel